UBS Group’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

UBS Group’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-59,864	Closed	-$12K	–	8700
2019 Q3	$12K	Sell	59,864 -4,620	-7%	-$3.13K	﹤0.01%	7084
2019 Q2	$56K	Buy	64,484 +32,386	+101%	+$50.7K	﹤0.01%	5829
2019 Q1	$75K	Buy	32,098 +23,042	+254%	+$62.4K	﹤0.01%	5283
2018 Q4	$21K	Buy	9,056 +4,170	+85%	+$36.8K	﹤0.01%	6775
2018 Q3	$72K	Buy	4,886 +586	+14%	+$9.31K	﹤0.01%	5864
2018 Q2	$65K	Buy	4,300 +1,061	+33%	+$18K	﹤0.01%	5793
2018 Q1	$61K	Buy	3,239 +266	+9%	+$4.65K	﹤0.01%	5571
2017 Q4	$54K	Buy	2,973 +485	+19%	+$10.3K	﹤0.01%	5790
2017 Q3	$55K	Buy	+2,488	New	+$54.6K	﹤0.01%	5733

Other funds holding SNNA

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Private Ocean San Rafael, California $1.13B AUM 11.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group's SNNA Position: Q4 2019 in Review

UBS Group sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2019, closing a stake of 59,864 shares — an estimated $12K sold.

UBS Group first reported a position in SNNA in Q3 2017 and held it in 9 quarters. The position peaked at $75K in Q1 2019. 4 funds tracked by Wall St. Rank hold SNNA as of Q4 2019.

UBS Group reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
UBS Group sold 59,864 Sienna Biopharmaceuticals, Inc. shares in Q4 2019, an estimated $12K.
UBS Group first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 9 quarters.
UBS Group's Sienna Biopharmaceuticals, Inc. position peaked at $75K in Q1 2019.
4 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2019.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.